Mr. Wolfgang Probst reports

BIONXT SOLUTIONS ANNOUNCES DELAY IN FILING 2024 ANNUAL FINANCIAL STATEMENTS

Bionxt Solutions Inc.'s annual financial statements for the year ended Dec. 31, 2024, the related management's discussion and analysis, and certifications of the chief executive officer and the chief financial officer have not been filed by the required filing deadline of April 30, 2025, due to delays in receiving certain financial information required for the annual filings. The company is working diligently with its auditor to complete the annual filings and expects to be able to file the annual filings on or before June 28, 2025.

The company has applied to the applicable securities regulatory authorities and received a management cease trade order imposed against the CEO and CFO of the company precluding them from trading securities of the company. The MCTO will be in effect until the annual filings are filed, and requires that they be filed on or before June 30, 2025.

Until the annual filings are filed, the company intends to satisfy the provisions of the alternative information guidelines set out in National Policy 12-203 (Management Cease Trade Orders). The company confirms that there is no other material information relating to its affairs that has not been generally disclosed.

About Bionxt Solutions Inc.

Bionxt is a bioscience innovator focused on next-generation drug delivery technologies, diagnostic screening systems and active pharmaceutical ingredient development. The company's proprietary platforms -- sublingual (thin film), transdermal (skin patch) and oral (enteric-coated tablets) -- target key therapeutic areas, including autoimmune diseases, neurological disorders and longevity.

With research and development operations in North America and Europe, Bionxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. Bionxt is committed to improving health care by delivering precise, patient-centric solutions that enhance treatment outcomes worldwide.

Bionxt is listed on the Canadian Securities Exchange and the OTC Markets, and trades in Germany under WKN: A3D1K3.

We seek Safe Harbor.